CEL-SCI CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND SIX MONTH WARRANTS

Cel-Sci's picture
Printer-friendly versionPrinter-friendly version

Vienna, VA, April 11, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it intends to offer and sell common stock and six month warrants in a "best efforts" underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed.

Dawson James Securities, Inc, and Laidlaw & Company (UK) Ltd. are acting as joint book-running managers and underwriters for the proposed offering.

A shelf registration statement and accompanying base prospectus on Form S-3 relating to the securities was filed with the Securities and Exchange Commission and is effective. The offering may be made only by means of a prospectus, copies of which may be obtained, when available, from the offices of Laidlaw & Company (UK) Ltd., 546 Fifth Avenue, 5th Floor, New York, NY, 10036, telephone: 212-953-4900, or from Dawson James Securities, 1 North Federal Highway, Suite 500, Boca Raton, FL 33432, telephone: 561-391-5555.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About CEL-SCI Corporation

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with its future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

Safe Harbor Statement

When used in this release, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, without limitation, the company's ability to complete the proposed public offering of its common stock and warrants described above. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

News Source : CEL-SCI CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND SIX MONTH WARRANTS
Copy this html code to your website/blog to embed this press release.

Press Release

Syndicate content
Post date
01/14/2016 - 08:58 CEL-SCI CORPORATION TO PRESENT AT THE NOBLE FINANCIAL CAPITAL MARKETS' 12TH ANNUAL INVESTOR CONFERENCE
01/05/2016 - 14:45 CEL-SCI REPORTS RECORD YEAR FOR PATIENT ENROLLMENT WITH 75% INCREASE IN ITS GLOBAL PHASE 3 HEAD AND NECK CANCER TRIAL
12/01/2015 - 22:33 CEL-SCI REPORTS MONTHLY PATIENT ENROLLMENT IN NOVEMBER FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
11/30/2015 - 20:18 CEL-SCI CORPORATION TO PRESENT AT THE LD MICRO MAIN EVENT
11/17/2015 - 15:06 CEL-SCI IS GRANTED A NEW EUROPEAN PATENT ON ITS PHASE 3 INVESTIGATIONAL CANCER IMMUNOTHERAPY MULTIKINE
11/04/2015 - 10:16 CEL-SCI's RHEUMATOID ARTHRITIS VACCINE SELECTED FOR COMMERCIALIZATION & PROGRAM NICHE ANALYSIS PLAN BY U.S. NATIONAL INSTITUTES OF HEALTH
11/02/2015 - 12:05 CEL-SCI REPORTS RECORD MONTHLY PATIENT ENROLLMENT IN OCTOBER FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
10/28/2015 - 14:05 CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING FOR GROSS PROCEEDS OF $11.5 MILLION
10/23/2015 - 08:20 CEL-SCI PRICES PUBLIC OFFERING FOR UP TO $12 MILLION
10/14/2015 - 10:29 CEL-SCI TO RECEIVE UP TO $5,000,000 IN LITIGATION FUNDING TO SUPPORT ITS ARBITRATION SUIT AGAINST FORMER CRO
10/05/2015 - 20:49 ERGOMED INCREASES ITS CO-DEVELOPMENT CONTRIBUTION UP TO $12,000,000 IN CEL-SCI'S PHASE 3 HEAD AND NECK CANCER TRIAL
09/01/2015 - 02:16 CEL-SCI REPORTS AUGUST PATIENT ENROLLMENT FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
08/03/2015 - 07:56 CEL-SCI REPORTS RECORD MONTHLY PATIENT ENROLLMENT IN JULY FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
07/01/2015 - 10:13 CEL-SCI REPORTS JUNE PATIENT ENROLLMENT IN ITS PHASE 3 HEAD AND NECK CANCER TRIAL
06/16/2015 - 08:47 CEL-SCI TO PRESENT AT THE 2015 BIO INTERNATIONAL CONVENTION
06/08/2015 - 10:50 CEL-SCI IS CLEARED TO START PATIENT ENROLLMENT FOR ITS PHASE 3 CANCER IMMUNOTHERAPY TRIAL IN THAILAND
06/01/2015 - 07:55 CEL-SCI REPORTS MAY PATIENT ENROLLMENT IN ITS PHASE 3 HEAD AND NECK CANCER TRIAL
05/29/2015 - 14:57 CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING FOR GROSS PROCEEDS OF $16 MILLION
05/27/2015 - 11:12 CEL-SCI TO PRESENT AT THE 2015 MARCUM MICROCAP CONFERENCE
05/22/2015 - 07:56 CEL-SCI PRICES UP TO $16 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS
Copy and paste this code to display this page on your website .
Syndicate content